This combination tablet contains Sitagliptin 100 mg, Pioglitazone Hydrochloride 15 mg, and Metformin Hydrochloride 500 mg (SR). It is formulated in a sustained-release form for effective management of type 2 diabetes mellitus. Sitagliptin is a DPP-4 inhibitor that increases incretin levels, helping regulate blood sugar by enhancing insulin secretion and reducing glucagon levels. Pioglitazone improves insulin sensitivity in muscles and the liver, helping the body use insulin more efficiently. Metformin (SR) lowers glucose production in the liver and improves insulin sensitivity. The sustained-release formulation ensures gradual drug release, reducing gastrointestinal side effects and allowing once-daily dosing. This triple combination therapy is ideal for patients whose blood sugar is not adequately controlled by diet, exercise, or single-drug therapy. It helps maintain steady glycemic control, reduces the risk of complications, and improves overall metabolic health.
